MannKind Corp MNKD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $6.39
- Day Range
- $6.23–6.44
- 52-Week Range
- $3.17–6.92
- Bid/Ask
- $6.27 / $6.35
- Market Cap
- $1.72 Bil
- Volume/Avg
- 2.2 Mil / 2.6 Mil
Key Statistics
- Price/Earnings (Normalized)
- 46.16
- Price/Sales
- 6.92
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 414
- Website
- https://www.mannkindcorp.com
Comparables
Valuation
|
Metric
|
MNKD
|
TRVI
|
APLT
|
|---|---|---|---|
Price/Earnings (Normalized) | 46.16 | — | — |
Price/Book Value | — | 3.44 | 13.34 |
Price/Sales | 6.92 | — | 2,963.35 |
Price/Cash Flow | 35.63 | — | — |
Price/Earnings
MNKD
TRVI
APLT
Financial Strength
|
Metric
|
MNKD
|
TRVI
|
APLT
|
|---|---|---|---|
Quick Ratio | 3.39 | 10.29 | 2.21 |
Current Ratio | 4.07 | 10.68 | 2.30 |
Interest Coverage | 1.12 | −4,780.89 | — |
Quick Ratio
MNKD
TRVI
APLT
Profitability
|
Metric
|
MNKD
|
TRVI
|
APLT
|
|---|---|---|---|
Return on Assets (Normalized) | 10.03% | −40.88% | −80.98% |
Return on Equity (Normalized) | — | −44.19% | −319.42% |
Return on Invested Capital (Normalized) | 264.03% | −48.62% | −315.20% |
Return on Assets
MNKD
TRVI
APLT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Yfvlvshbw | Wjdgm | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Nynjllsth | Dbkfy | $119.6 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Xtbrdcbys | Lltdltg | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Rmywjkd | Tqyyh | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Lhzqcbjdm | Ptzz | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Vrrtqtbhm | Bzyg | $28.0 Bil | |||
| Moderna Inc
MRNA
| Tmdbwqkxq | Vkgp | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Hdjllly | Dvlxm | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Szvqttktx | Ydxfpsb | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Mjcftpwg | Ppfygx | $12.6 Bil |
United States